{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T01:14:08Z","timestamp":1778030048921,"version":"3.51.4"},"reference-count":85,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2023,3,12]],"date-time":"2023-03-12T00:00:00Z","timestamp":1678579200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Treatment of hepatitis C (HCV) has been revolutionized with the introduction of direct-acting antivirals (DAAs). Patients can be treated at more advanced stages of liver disease, with a growing number of cirrhotic patients achieving sustained virological response (SVR). Long-term outcomes for cured patients and the optimal follow-up care of patients after SVR are yet to be defined, because most studies on cirrhotic patients cured with DAAs have a short follow-up period. There are many open questions related to patient management after viral eradication with DAAs, such as which could be the most reliable non-invasive tool to predict liver-related complications, or to what extent viral eradication reduces the risk of liver disease progression in the long term. Growing evidence supports the personalization of follow-up care based on individual risk. The aim of this narrative review is to analyze the impact of viral eradication with DAAs on clinically significant portal hypertension, hepatocellular carcinoma, and extrahepatic manifestations, as well as to summarize indications for optimal follow-up care of HCV patients treated with DAAs.<\/jats:p>","DOI":"10.3390\/jcm12062195","type":"journal-article","created":{"date-parts":[[2023,3,13]],"date-time":"2023-03-13T03:03:57Z","timestamp":1678676637000},"page":"2195","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Outcomes and Follow-Up after Hepatitis C Eradication with Direct-Acting Antivirals"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2638-2559","authenticated-orcid":false,"given":"Erica Nicola","family":"Lynch","sequence":"first","affiliation":[{"name":"Department of Surgery, Oncology and Gastroenterology, University of Padua, 35122 Padova, Italy"},{"name":"Department of Medical Biotechnologies, University of Siena, 53100 Siena, Italy"},{"name":"Gastroenterology Research Unit, Department of Experimental and Clinical Biomedical Sciences \u201cMario Serio\u201d, University of Florence, 50134 Florence, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4127-8941","authenticated-orcid":false,"given":"Francesco Paolo","family":"Russo","sequence":"additional","affiliation":[{"name":"Department of Surgery, Oncology and Gastroenterology, University of Padua, 35122 Padova, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,3,12]]},"reference":[{"key":"ref_1","unstructured":"World Health Organization (2021). Global Progress Report on HIV, Viral Hepatitis and Sexually Transmitted Infections, World Health Organization."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1016\/j.jhep.2020.08.018","article-title":"EASL recommendations on treatment of hepatitis C: Final update of the series","volume":"73","author":"Pawlotsky","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1016\/j.jhep.2014.07.012","article-title":"Natural history of hepatitis C","volume":"61","author":"Westbrook","year":"2014","journal-title":"J. Hepatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1002\/jmv.10448","article-title":"Spontaneous elimination of serum hepatitis C virus (HCV) RNA in chronic HCV carriers: A population-based cohort study","volume":"71","author":"Watanabe","year":"2003","journal-title":"J. Med. Virol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/S0168-8278(99)80028-2","article-title":"Spontaneous negativation of serum hepatitis C virus RNA is a rare event in type C chronic liver diseases: Analysis of HCV RNA in 320 patients who were followed for more than 3 years","volume":"31","author":"Yokosuka","year":"1999","journal-title":"J. Hepatol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1136\/gut.50.5.693","article-title":"Infection rate and spontaneous seroreversion of anti-hepatitis C virus during the natural course of hepatitis C virus infection in the general population","volume":"50","author":"Chionne","year":"2002","journal-title":"Gut"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1056\/NEJM198612183152503","article-title":"Treatment of Chronic Non-A, Non-B Hepatitis with Recombinant Human Alpha Interferon","volume":"315","author":"Hoofnagle","year":"1986","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1056\/NEJM198911303212203","article-title":"Treatment of Chronic Hepatitis C with Recombinant Interferon Alfa","volume":"321","author":"Davis","year":"1989","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1002\/hep.510240405","article-title":"Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: Effects of dose and duration","volume":"24","author":"Poynard","year":"1996","journal-title":"Hepatology"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJMoa020047","article-title":"Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus Infection","volume":"347","author":"Fried","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/s41575-022-00608-8","article-title":"Breakthroughs in hepatitis C research: From discovery to cure","volume":"19","author":"Manns","year":"2022","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Dietz, C., and Maasoumy, B. (2022). Direct-Acting Antiviral Agents for Hepatitis C Virus Infection\u2014From Drug Discovery to Successful Implementation in Clinical Practice. Viruses, 14.","DOI":"10.3390\/v14061325"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.jhep.2020.11.021","article-title":"Clinical outcomes following DAA therapy in patients with HCV-related cirrhosis depend on disease severity","volume":"74","author":"Krassenburg","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1056\/NEJMoa1613512","article-title":"Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection","volume":"376","author":"Gordon","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1002\/hep.31060","article-title":"Hepatitis C Guidance 2019 Update: American Association for the Study of Liver Diseases\u2013Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection","volume":"71","author":"Ghany","year":"2019","journal-title":"Hepatology"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1007\/s12072-016-9717-6","article-title":"APASL consensus statements and recommendation on treatment of hepatitis C","volume":"10","author":"Omata","year":"2016","journal-title":"Hepatol. Int."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1016\/j.cgh.2007.02.022","article-title":"Effect of Sustained Viral Response on Hepatic Venous Pressure Gradient in Hepatitis C\u2013Related Cirrhosis","volume":"5","author":"Roberts","year":"2007","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1002\/hep.23528","article-title":"Sustained virologic response prevents the development of esophageal varices in compensated, Child-Pugh class A hepatitis C virus-induced cirrhosis. A 12-year prospective follow-up study","volume":"51","author":"Bruno","year":"2010","journal-title":"Hepatology"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.jhep.2016.10.017","article-title":"Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication","volume":"66","author":"Feld","year":"2017","journal-title":"J. Hepatol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1016\/j.cgh.2020.02.044","article-title":"Disease Progression in Patients With Hepatitis C Virus Infection Treated With Direct-Acting Antiviral Agents","volume":"18","author":"Mendizabal","year":"2020","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/j.jhep.2021.07.003","article-title":"Fibrogenic signals persist in DAA-treated HCV patients after sustained virological response","volume":"75","author":"Montaldo","year":"2021","journal-title":"J. Hepatol."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Devhare, P.B., Sasaki, R., Shrivastava, S., Di Bisceglie, A.M., Ray, R., and Ray, R.B. (2017). Exosome-Mediated Intercellular Communication between Hepatitis C Virus-Infected Hepatocytes and Hepatic Stellate Cells. J. Virol., 91.","DOI":"10.1128\/JVI.00349-17"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.omtn.2019.01.006","article-title":"Exosomal Transmission of MicroRNA from HCV Replicating Cells Stimulates Transdifferentiation in Hepatic Stellate Cells","volume":"14","author":"Kim","year":"2019","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.jhep.2019.10.005","article-title":"Non-invasive prediction of liver-related events in patients with HCV-associated compensated advanced chronic liver disease after oral antivirals","volume":"72","author":"Pons","year":"2019","journal-title":"J. Hepatol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s43066-022-00188-x","article-title":"Impact of sustained virologic response in regression of portal hypertension in Egyptian patients with hepatitis C virus-associated cirrhosis and portal hypertension","volume":"12","author":"Faheem","year":"2022","journal-title":"Egypt. Liver J."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/j.jhep.2020.05.050","article-title":"Clinical outcome and hemodynamic changes following HCV eradication with oral antiviral therapy in patients with clinically significant portal hypertension","volume":"73","author":"Lens","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_27","first-page":"959","article-title":"Baveno VII \u2013 Renewing consensus in portal hypertension","volume":"76","author":"Bosch","year":"2021","journal-title":"J. Hepatol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1016\/j.jhep.2022.08.025","article-title":"Non-invasive tests for clinically significant portal hypertension after HCV cure","volume":"77","author":"Semmler","year":"2022","journal-title":"J. Hepatol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1111\/jvh.13587","article-title":"Non-invasive assessment of fibrosis regression and portal hypertension in patients with advanced chronic hepatitis C virus (HCV)-associated liver disease and sustained virologic response (SVR): 3 years follow-up of a prospective longitudinal study","volume":"28","author":"Knop","year":"2021","journal-title":"J. Viral Hepat."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"100289","DOI":"10.1016\/j.jhepr.2021.100289","article-title":"Risk of hepatocellular carcinoma after HCV eradication: Determining the role of portal hypertension by measuring spleen stiffness","volume":"3","author":"Dajti","year":"2021","journal-title":"JHEP Rep."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/s41575-019-0186-y","article-title":"A global view of hepatocellular carcinoma: Trends, risk, prevention and management","volume":"16","author":"Yang","year":"2019","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"329","DOI":"10.7326\/0003-4819-158-5-201303050-00005","article-title":"Eradication of hepatitis c virus infection and the development of hepatocellular carcinoma: A meta-analysis of observational studies","volume":"158","author":"Morgan","year":"2013","journal-title":"Ann. Intern. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/j.jhep.2017.07.025","article-title":"Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: A systematic review, meta-analyses, and meta-regression","volume":"67","author":"Waziry","year":"2017","journal-title":"J. Hepatol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.jhep.2021.11.025","article-title":"HCC risk stratification after cure of hepatitis C in patients with compensated advanced chronic liver disease","volume":"76","author":"Semmler","year":"2021","journal-title":"J. Hepatol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1055\/s-0040-1702944","article-title":"Postsustained Virological Response Management in Hepatitis C Patients","volume":"40","author":"Masetti","year":"2020","journal-title":"Semin. Liver Dis."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/j.cgh.2018.10.038","article-title":"Factors Associated With Increased Risk of De Novo or Recurrent Hepatocellular Carcinoma in Patients With Cirrhosis Treated With Direct-Acting Antivirals for HCV Infection","volume":"17","author":"Degasperi","year":"2019","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1097\/MEG.0000000000002358","article-title":"Adherence to regular surveillance visits for hepatocellular carcinoma in patients with chronic hepatitis C virus infection who achieved sustained virologic response","volume":"34","author":"Toyoda","year":"2022","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"9954","DOI":"10.1038\/srep09954","article-title":"Systematic Review: Impact of Interferon-based Therapy on HCV-related Hepatocellular Carcinoma","volume":"5","author":"Hsu","year":"2015","journal-title":"Sci. Rep."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Kusano, H., Akiba, J., Ogasawara, S., Sanada, S., Yasumoto, M., Nakayama, M., Ueda, K., Ueda, K., Kurita, T., and Todoroki, K. (2013). Pegylated Interferon-\u03b12a Inhibits Proliferation of Human Liver Cancer Cells In Vitro and In Vivo. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0083195"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.jhep.2016.04.008","article-title":"Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy","volume":"65","author":"Reig","year":"2016","journal-title":"J. Hepatol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1016\/j.jhep.2016.06.009","article-title":"Unexpected high incidence of hepatocellular carcinoma in cirrhotic patients with sustained virologic response following interferon-free direct-acting antiviral treatment","volume":"65","author":"Kozbial","year":"2016","journal-title":"J. Hepatol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1016\/j.jhep.2016.07.027","article-title":"High incidence of hepatocellular carcinoma following successful interferon-free antiviral therapy for hepatitis C associated cirrhosis","volume":"65","author":"Cardoso","year":"2016","journal-title":"J. Hepatol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.jhep.2020.03.030","article-title":"Undefined\/non-malignant hepatic nodules are associated with early occurrence of HCC in DAA-treated patients with HCV-related cirrhosis","volume":"73","author":"Sangiovanni","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.jhep.2017.10.033","article-title":"The risk of hepatocellular carcinoma in cirrhotic patients with hepatitis C and sustained viral response: Role of the treatment regimen","volume":"68","author":"Innes","year":"2018","journal-title":"J. Hepatol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jhep.2017.08.030","article-title":"HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular carcinoma","volume":"68","author":"Ioannou","year":"2018","journal-title":"J. Hepatol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1053\/j.gastro.2017.06.012","article-title":"Risk of Hepatocellular Cancer in HCV Patients Treated With Direct-Acting Antiviral Agents","volume":"153","author":"Kanwal","year":"2017","journal-title":"Gastroenterology"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/apt.14823","article-title":"Systematic review with meta-analysis: Recurrence of hepatocellular carcinoma following direct-acting antiviral therapy","volume":"48","author":"Saraiya","year":"2018","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1136\/gutjnl-2020-323663","article-title":"Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: An individual patient data meta-analysis","volume":"71","author":"Sapena","year":"2022","journal-title":"Gut"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1136\/gutjnl-2021-324288","article-title":"End of the story: Direct-acting antiviral agents are not associated with recurrence of hepatocellular carcinoma","volume":"71","author":"Hernaez","year":"2021","journal-title":"Gut"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1093\/infdis\/jis385","article-title":"HCV Study Group Chronic Hepatitis C Virus Infection Increases Mortality from Hepatic and Extrahepatic Diseases: A Community-Based Long-Term Prospective Study","volume":"206","author":"Lee","year":"2012","journal-title":"J. Infect. Dis."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0140-6736(18)32111-1","article-title":"Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: A prospective cohort study","volume":"393","author":"Carrat","year":"2019","journal-title":"Lancet"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1053\/j.gastro.2015.09.007","article-title":"Hepatitis C Virus Infection Is Associated With Increased Cardiovascular Mortality: A Meta-Analysis of Observational Studies","volume":"150","author":"Petta","year":"2016","journal-title":"Gastroenterology"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jare.2016.06.001","article-title":"Hepatitis C virus and cardiovascular: A review","volume":"8","author":"Petta","year":"2016","journal-title":"J. Adv. Res."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1053\/j.gastro.2016.09.009","article-title":"Eradication of Hepatitis C Virus Infection in Patients with Cirrhosis Reduces Risk of Liver and Non-Liver Complications","volume":"152","author":"Nahon","year":"2017","journal-title":"Gastroenterology"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.ahj.2017.10.024","article-title":"Prognostic value of viral eradication for major adverse cardiovascular events in hepatitis C cirrhotic patients","volume":"198","author":"Cacoub","year":"2017","journal-title":"Am. Heart J."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1016\/j.numecd.2021.04.016","article-title":"Impact of direct acting antivirals (DAAs) on cardiovascular events in HCV cohort with pre-diabetes","volume":"31","author":"Sasso","year":"2021","journal-title":"Nutr. Metab. Cardiovasc. Dis."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1111\/jvh.13523","article-title":"Liver and cardiovascular mortality after hepatitis C virus eradication by DAA: Data from RESIST-HCV cohort","volume":"28","author":"Calvaruso","year":"2021","journal-title":"J. Viral Hepat."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"100555","DOI":"10.1016\/j.aohep.2021.100555","article-title":"LDL particle size and antioxidant HDL function improve after sustained virological response in patients with chronic HCV","volume":"27","author":"Vargas","year":"2021","journal-title":"Ann. Hepatol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1053\/jhep.2000.8270","article-title":"Hepatitis C\u2013related cirrhosis: A predictor of diabetes after liver transplantation","volume":"32","author":"Bigam","year":"2000","journal-title":"Hepatology"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/j.1478-3231.2007.01630.x","article-title":"Prevalence of diabetes mellitus and insulin resistance in patients with chronic hepatitis C: Comparison with hepatitis B virus-infected and hepatitis C virus-cleared patients","volume":"28","author":"Imazeki","year":"2008","journal-title":"Liver Int."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.jinf.2004.06.001","article-title":"Prevalence of diabetes mellitus and dyslipidemia among antiretroviral na\u0457ve patients co-infected with hepatitis C virus (HCV) and HIV-1 compared to patients without co-infection","volume":"50","author":"Visnegarwala","year":"2005","journal-title":"J. Infect."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12902-022-01198-x","article-title":"HCV infection characteristics, treatment uptake and outcomes in patient with diabetes mellitus","volume":"22","author":"Angel","year":"2022","journal-title":"BMC Endocr. Disord."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/j.1872-034X.2007.00052.x","article-title":"Diabetes mellitus reduces the therapeutic effectiveness of interferon-?2b plus ribavirin therapy in patients with chronic hepatitis C","volume":"37","author":"Konishi","year":"2007","journal-title":"Hepatol. Res."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1053\/j.gastro.2004.12.049","article-title":"Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients","volume":"128","author":"Viloria","year":"2005","journal-title":"Gastroenterology"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1038\/s41598-020-58786-x","article-title":"Hepatitis C Virus Clearance with Glucose Improvement and Factors Affecting the Glucose Control in Chronic Hepatitis C Patients","volume":"10","author":"Yuan","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1111\/jvh.13215","article-title":"Hepatitis C virus eradication with direct-acting antiviral improves insulin resistance","volume":"27","author":"Russo","year":"2019","journal-title":"J. Viral Hepat."},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"V\u00e1ncsa, S., N\u00e9meth, D., Hegyi, P., Szak\u00e1cs, Z., Farkas, A., Kiss, S., Kanjo, A., Sarl\u00f3s, P., Er\u0151ss, B., and P\u00e1r, G. (2021). Diabetes Mellitus Increases the Risk of Hepatocellular Carcinoma After Direct-Acting Antiviral Therapy: Systematic Review and Meta-Analysis. Front. Med., 8.","DOI":"10.3389\/fmed.2021.744512"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1053\/j.gastro.2018.04.024","article-title":"Long-Term Outcomes of Patients With HCV-Associated Cryoglobulinemic Vasculitis After Virologic Cure","volume":"155","author":"Bonacci","year":"2018","journal-title":"Gastroenterology"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"627","DOI":"10.14309\/ajg.0000000000001667","article-title":"Relapse of Hepatitis C Virus Cryoglobulinemic Vasculitis After Sustained Viral Response After Interferon-Free Direct-Acting Antivirals","volume":"117","author":"Fayed","year":"2022","journal-title":"Am. J. Gastroenterol."},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Danishwar, M., Jamil, Z., Khan, S., Nakhla, M., Ahmad, I., Ali, M.A., and Lau, D.T.Y. (2022). Persistence of Cryoglobulinemic Vasculitis after DAA Induced HCV Cure. J. Clin. Med., 11.","DOI":"10.3390\/jcm11040984"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1002\/hep.32281","article-title":"A prospective study of direct-acting antiviral effectiveness and relapse risk in HCV cryoglobulinemic vasculitis by the Italian PITER cohort","volume":"76","author":"Kondili","year":"2021","journal-title":"Hepatology"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"S82","DOI":"10.1016\/j.jhep.2016.06.011","article-title":"Hepatitis C virus infection and chronic kidney disease: Time for reappraisal","volume":"65","author":"Cacoub","year":"2016","journal-title":"J. Hepatol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"3801","DOI":"10.1007\/s10620-015-3801-y","article-title":"Hepatitis C Virus Infection Increases the Risk of Developing Chronic Kidney Disease: A Systematic Review and Meta-Analysis","volume":"60","author":"Fabrizi","year":"2015","journal-title":"Dig. Dis. Sci."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1002\/hep.1840360621","article-title":"Extrahepatic manifestations of hepatitis C among United States male veterans","volume":"36","year":"2002","journal-title":"Hepatology"},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"AASLD-IDSA HCV Guidance Panel (2018). Hepatitis C Guidance 2018 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection. Clin. Infect. Dis., 67, 1477\u20131492.","DOI":"10.1093\/cid\/ciy585"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1016\/j.kint.2022.07.012","article-title":"Executive Summary of the KDIGO 2022 Clinical Practice Guideline for the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney Disease","volume":"102","author":"Martin","year":"2022","journal-title":"Kidney Int."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.kint.2019.04.030","article-title":"Direct-acting antiviral therapy slows kidney function decline in patients with Hepatitis C virus infection and chronic kidney disease","volume":"97","author":"Sise","year":"2019","journal-title":"Kidney Int."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1111\/apt.15240","article-title":"The effects of sustained virological response to direct-acting anti-viral therapy on the risk of extrahepatic manifestations of hepatitis C infection","volume":"49","author":"Christie","year":"2019","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1038\/ajg.2016.498","article-title":"Changing Concepts of Cirrhotic Coagulopathy","volume":"112","author":"Tripodi","year":"2017","journal-title":"Am. J. Gastroenterol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1111\/jth.14011","article-title":"Increased factor VIII plays a significant role in plasma hypercoagulability phenotype of patients with cirrhosis","volume":"16","author":"Sinegre","year":"2018","journal-title":"J. Thromb. Haemost."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1111\/liv.13873","article-title":"Reversal of hypercoagulability in patients with HCV-related cirrhosis after treatment with direct-acting antivirals","volume":"38","author":"Russo","year":"2018","journal-title":"Liver Int."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1111\/jvh.12518","article-title":"The anti-lymphoma activity of antiviral therapy in HCV-associated B-cell non-Hodgkin lymphomas: A meta-analysis","volume":"23","author":"Arcaini","year":"2016","journal-title":"J. Viral Hepat."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/liv.14781","article-title":"Patient-reported outcomes 12 months after hepatitis C treatment with direct-acting antivirals: Results from the PROP UP study","volume":"41","author":"Serper","year":"2021","journal-title":"Liver Int."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.cgh.2021.01.026","article-title":"Long-term Patient-Centered Outcomes in Cirrhotic Patients With Chronic Hepatitis C After Achieving Sustained Virologic Response","volume":"20","author":"Younossi","year":"2021","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1158\/1055-9965.EPI-16-0747","article-title":"Improved Performance of Serum Alpha-Fetoprotein for Hepatocellular Carcinoma Diagnosis in HCV Cirrhosis with Normal Alanine Transaminase","volume":"26","author":"Yang","year":"2017","journal-title":"Cancer Epidemiol. Biomark. Prev."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/6\/2195\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:53:06Z","timestamp":1760122386000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/6\/2195"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,12]]},"references-count":85,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,3]]}},"alternative-id":["jcm12062195"],"URL":"https:\/\/doi.org\/10.3390\/jcm12062195","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,12]]}}}